RX 821002 hydrochloride
Potent, selective α2-adrenoceptor antagonist with very low affinity for imidazoline sites. Displays selectivity for the α2D over the α2A subtypes (pKd values are 9.7 and 8.2 respectively).
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 270.72. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.69 mL||18.47 mL||36.94 mL|
|5 mM||0.74 mL||3.69 mL||7.39 mL|
|10 mM||0.37 mL||1.85 mL||3.69 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References are publications that support the products' biological activity.
Erdbrugger et al (1995) Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H]rauwolscine? A comparison of nine tissues and cell lines. J.Pharmacol.Exp.Ther. 273 1287 PMID: 7791100
O'Rourke et al (1994) Characterisation of [3H]RX 821002 binding to alpha-2 adrenergic receptor subtypes. J.Pharmacol.Exp.Ther. 268 1362 PMID: 7908054
Trendelenburg et al (1996) Antagonists that differentiate between α2A- and α2D-adrenoceptors. Naunyn Schmiedebergs Arch.Pharmacol. 353 245 PMID: 8692278
If you know of a relevant reference for RX 821002 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: RX 821002 hydrochloride, supplier, Potent, selective, α2D-adrenoceptor, alpha2D-adrenoceptor, a2d-adrenoceptor, α2d-adrenergic, alpha2d-adrenergic, a2d-adrenergic, antagonists, Receptors, RX821002, hydrochloride, Adrenergic, Alpha-2, Receptors, Adrenergic, Alpha-2, Receptors, Tocris Bioscience
3 Citations for RX 821002 hydrochloride
Citations are publications that use Tocris products. Selected citations for RX 821002 hydrochloride include:
Alves et al (2014) Both α1- and α2-adrenoceptors in the insular cortex are involved in the cardiovascular responses to acute restraint stress in rats. J Chem Biol 9 e83900 PMID: 24404141
Crestani et al (2008) Both alpha1 and alpha2-adrenoceptors mediate the cardiovascular responses to noradrenaline microinjected into the bed nucleus of the stria terminal of rats. Br J Pharmacol 153 583 PMID: 18037912
Hott et al (2012) Both α1- and β1-adrenoceptors in the bed nucleus of the stria terminalis are involved in the expression of conditioned contextual fear. Br J Pharmacol 167 207 PMID: 22506532
Do you know of a great paper that uses RX 821002 hydrochloride from Tocris? If so please let us know.
Reviews for RX 821002 hydrochloride
There are currently no reviews for this product. Be the first to review RX 821002 hydrochloride and earn rewards!
Have you used RX 821002 hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.